Abstract

Clofibrate (Atromid-S - ICI) has been used for almost 20 years in the management of patients with hyperlipidaemia. In this time it has been possible to assess the long-term risks of the drug and its place in primary and secondary prevention of coronary heart disease. These factors, and the introduction of alternative therapy, have prompted this article.